Intravesical Ad-IFNα causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-α protein

被引:76
作者
Benedict, WF
Tao, ZM
Kim, CS
Zhang, XQ
Zhou, JH
Adam, L
McConkey, DJ
Papageorgiou, A
Munsell, M
Philopena, J
Engler, H
Demers, W
Maneval, DC
Dinney, CPN
Connor, RJ
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Cell Biol, Houston, TX 77030 USA
[4] Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[5] Canji Inc, San Diego, CA USA
关键词
enhanced adenoviral gene transfer; gene therapy; orthotopic bladder cancer model; superficial human bladder cancer; overcoming interferon protein resistance;
D O I
10.1016/j.ymthe.2004.05.027
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
We have produced prolonged, high local concentrations of interferon in vivo by intravesical instillation of adenoviruses encoding interferon-alpha, (Ad-IFNalpha) together with the gene transferenhancing agent Syn3. We found sustained interferon protein levels for days, both in normal mouse urotheliurn and in human bladder cancer cells growing as superficial bladder tumors in nude mice using an orthotopic bladder model developed by us. Tumor burden in the bladder was determined utilizing cancer cells containing the green fluorescent protein. Marked tumor regression was observed following two 1-h exposures of Ad-IFNalpha/Syn3 and little or no cytotoxicity was detected in normal cells. Similar intravesical instillation of clinically relevant concentrations of IFN protein alone or Ad-IFNalpha without Syn3 was ineffective. Surprisingly, in vitro, Ad-IFNalpha also caused caspase-dependent death of bladder cancer cell lines that were resistant to high concentrations of IFNalpha protein, including the cell line used in vivo. These findings demonstrate that Ad-IFNalpha can overcome resistance to IFNalpha protein both in vitro and in vivo and support evaluation of intravesical Ad-IFNalpha/Syn3 for the treatment of superficial bladder cancer.
引用
收藏
页码:525 / 532
页数:8
相关论文
共 19 条
[1]   Selective expression of nonsecreted interferon by an adenoviral vector confers antiproliferative and antiviral properties and causes reduction of tumor growth in nude mice [J].
Ahmed, CMI ;
Wills, KN ;
Sugarman, BJ ;
Johnson, DE ;
Ramachandra, M ;
Nagabhushan, TL ;
Howe, JA .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2001, 21 (06) :399-408
[2]   Interferon α2b gene delivery using adenoviral vector causes inhibition of tumor growth in xenograft models from a variety of cancers [J].
Ahmed, CMI ;
Johnson, DE ;
Demers, GW ;
Engler, H ;
Howe, JA ;
Wills, KN ;
Wen, SF ;
Shinoda, J ;
Beltran, J ;
Nodelman, M ;
Machemer, T ;
Maneval, DC ;
Nagabhushan, TL ;
Sugarman, BJ .
CANCER GENE THERAPY, 2001, 8 (10) :788-795
[3]   In vivo tumor suppression by adenovirus-mediated interferon α2b gene delivery [J].
Ahmed, CMI ;
Sugarman, BJ ;
Johnson, DE ;
Bookstein, RE ;
Saha, DP ;
Nagabhushan, TL ;
Wills, KN .
HUMAN GENE THERAPY, 1999, 10 (01) :77-84
[4]   Superficial bladder cancer:: The role of interferon-α [J].
Belldegrun, AS ;
Franklin, JR ;
O'Donnell, MA ;
Gomella, LG ;
Klein, E ;
Neri, R ;
Nseyo, UO ;
Ratliff, TL ;
Williams, RD .
JOURNAL OF UROLOGY, 1998, 159 (06) :1793-1801
[5]   Identification of polyamides that enhance adenovirus-mediated gene expression in the urothelium [J].
Conner, RJ ;
Engler, H ;
Machemer, T ;
Philopena, JM ;
Horn, MT ;
Sutjipto, S ;
Maneval, DC ;
Youngster, S ;
Chan, TM ;
Bausch, J ;
McAuliffe, JP ;
Hindsgaul, O ;
Nagabhushan, TL .
GENE THERAPY, 2001, 8 (01) :41-48
[6]   Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer [J].
Dalbagni, G ;
Herr, HW .
UROLOGIC CLINICS OF NORTH AMERICA, 2000, 27 (01) :137-+
[7]   Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome [J].
Herr, HW .
JOURNAL OF UROLOGY, 2000, 163 (01) :60-61
[8]  
Izawa JI, 2002, CLIN CANCER RES, V8, P1258
[9]   USE OF RANKS IN ONE-CRITERION VARIANCE ANALYSIS [J].
KRUSKAL, WH ;
WALLIS, WA .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1952, 47 (260) :583-621
[10]   Salvage intravesical therapy with interferon-α2B plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed [J].
O'Donnell, MA ;
Krohn, J ;
DeWolf, WC .
JOURNAL OF UROLOGY, 2001, 166 (04) :1300-1304